June, 2004 Sponsored by Aventis Oncology
In this Issue

ASCO 2004OncoLink attended the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, in New Orleans, LA. Our reporters provided in-depth, up-to-the-minute coverage of sessions and presentations.

ASCO 2004 Plenary Session Highlights for Prostate cancer Patients!

SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA)

A multicenter phase III comparison of docetaxel + prednisone and mitoxantrone + prednisone in patients with hormone-refractory prostate cancer

...More Plenary Highlights

Exclusive Interview: Gemcitabine and paclitaxel as first line therapy for metastatic breast cancer. Senior Editor, Julia Draznin Maltzman, MD talks with Dr. Paolo Paoletti about this new standard.

Instant Fill in the Blanks Poetry: A creative interactive exercise from our Poet-in-Residence, Alysa Cumings

OncoLink Poll
OncoLink Monthly Poll
Prior to coming to the Oncologist, what research did you do?
OncoLink Survey
eNewsletter Survey
We are looking for your input. Please take a moment to fill-out our anonymous eNewsletter survey.


Oncology professionals who could not attend the annual meeting will benefit from the opportunity to read unbiased, balanced reviews on key presentations from the meeting.

OncoLink Editors Choice

June Editor's Choice: Fertile Hope is a national nonprofit organization dedicated to providing reproductive information, support and hope to cancer patients whose medical treatments present the risk of infertility.  

Contact Us   |   Unsubscribe   |   Privacy Policy